The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Inhibition of spore germination, growth, and toxin activity of clinically relevant C. difficile strains by gut microbiota derived secondary bile acids
Open accessAbstract
The changing epidemiology of Clostridium difficile infection over the past decades presents a significant challenge in the management of C. difficile associated diseases. The gastrointestinal tract microbiota provides colonization resistance against C. difficile, and growing evidence suggests that gut microbial derived secondary bile acids (SBAs) play a role. We hypothesized that the C. difficile life cycle; spore germination and outgrowth, growth, and toxin production, of strains that vary by age and ribotype will differ in their sensitivity to SBAs. C. difficile strains R20291 and CD196 (ribotype 027), M68 and CF5 (017), 630 (012), BI9 (001) and M120 (078) were used to define taurocholate (TCA) mediated spore germination and outgrowth, growth, and toxin activity in the absence and presence of gut microbial derived SBAs (deoxycholate, isodeoxycholate, lithocholate, isolithocholate, ursodeoxycholate, ω-muricholate, and hyodeoxycholate) found in the human and mouse large intestine. C. difficile strains varied in their rates of germination, growth kinetics, and toxin activity without the addition of SBAs. C. difficile M120, a highly divergent strain, had robust germination, growth, but significantly lower toxin activity compared to other strains. Many SBAs were able to inhibit TCA mediated spore germination and outgrowth, growth, and toxin activity in a dose dependent manner, but the level of inhibition and resistance varied across all strains and ribotypes. This study illustrates how clinically relevant C. difficile strains can have different responses when exposed to SBAs present in the gastrointestinal tract.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Since C. difficile is exquisitely sensitive to different BAs27,28, we employed sets of glycine and taurine-preferring BSHs to inhibit C. difficile (Figs. 3d, 4a and 5a).”
From Bile salt hydrolases shape the bile acid landscape and restrict Clostridioides difficile growth in the murine gut (2023) · cites this paper as [28]
In the citing paper
“Therefore, a healthy gut microbiota promotes colonization resistance against C. difficile through metabolism of bile acids to both reduce primary bile acids, which promote C. difficile spore germination, and increase secondary bile acids, which inhibit C. difficile vegetative growth.”
From Role of the gut microbiota in nutrient competition and protection against intestinal pathogen colonization (2023) · cites this paper as [56]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bile salt biotransformations by human intestinal bacteria
Ridlon, J. M., Kang, D.-J., & Hylemon, P. B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500013-jlr200 · Cited by 2,829
Burden of Clostridium difficile Infection in the United States
Lessa, F. C., Mu, Y., Bamberg, W. M., Beldavs, Z. G., Dumyati, G. K., Dunn, J. R., Farley, M. M., Holzbauer, S. M., Meek, J. I., Phipps, E. C., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1408913 · Cited by 2,641
Sayin, S. I., Wahlström, A., Felin, J., Jäntti, S., Marschall, H.-U., Bamberg, K., Angelin, B., Hyötyläinen, T., Orešič, M., & Bäckhed, F. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.01.003 · Cited by 2,331
The Enzymes, Regulation, and Genetics of Bile Acid Synthesis
Russell, D. W. (2003) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.72.121801.161712 · Cited by 2,069
An Epidemic, Toxin Gene–Variant Strain of Clostridium difficile
McDonald, L. C., Killgore, G., Thompson, A. D., Owens, R. C., Kazakova, S. V., Sambol, S. P., Johnson, S., & Gerding, D. N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051590 · Cited by 2,020
Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile
Buffie, C. G., Bucci, V., Stein, R. R., McKenney, P. T., Ling, L., Gobourne, A., No, D., Liu, H., Kinnebrew, M., Viale, A., et al. (2015) · Nature · doi:10.1038/nature13828 · Cited by 1,872
Bile acids: regulation of synthesis
Chiang, J. Y. L. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r900010-jlr200 · Cited by 1,515
Clostridium difficile Infection
Leffler, D. A., & LaMont, J. T. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1403772 · Cited by 1,501
Clostridium difficile infection: new developments in epidemiology and pathogenesis
Rupnik, M., Wilcox, M. H., & Gerding, D. N. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2164 · Cited by 1,380 · cited 1×
“Other PCR ribotypes such as 001, 053, and 106 have also been associated with outbreaks and severe cases [6].”
BackgroundTheriot, C. M., Koenigsknecht, M. J., Carlson, P. E., Hatton, G. E., Nelson, A. M., Li, B., Huffnagle, G. B., Z. Li, J., & Young, V. B. (2014) · Nature Communications · doi:10.1038/ncomms4114 · Cited by 974
Self-citation
Cited by
Sorted by citations
Bile acids and the gut microbiota: metabolic interactions and impacts on disease
Collins, S. L., Stine, J. G., Bisanz, J. E., Okafor, C. D., & Patterson, A. D. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00805-x · Cited by 1,214
Clostridium difficile infection: review
Czepiel, J., Dróżdż, M., Pituch, H. M., Kuijper, E. J., Perucki, W. H., Mielimonka, A., Goldman, S., Wultańska, D., Garlicki, A., & Biesiada, G. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03539-6 · Cited by 770
Novel bile acid biosynthetic pathways are enriched in the microbiome of centenarians
Sato, Y., Atarashi, K., Plichta, D. R., Arai, Y., Sasajima, S., Kearney, S. M., Suda, W., Takeshita, K., Sasaki, T., Okamoto, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03832-5 · Cited by 632
Antimicrobial Properties of Chitosan and Chitosan Derivatives in the Treatment of Enteric Infections
Yan, D., Li, Y., Liu, Y., Li, N., Zhang, X., & Yan, C. (2021) · Molecules · doi:10.3390/molecules26237136 · Cited by 656
Gut Microbiota and Colonization Resistance against Bacterial Enteric Infection
Ducarmon, Q. R., Zwittink, R. D., Hornung, B. V. H., van Schaik, W., Young, V. B., & Kuijper, E. J. (2019) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00007-19 · Cited by 566
Metadata
- Authors
- Thanissery, R., Winston, J. A., & Theriot, C. M.
- Affiliations
- North Carolina State University (US)
- Corresponding author
- Theriot, Casey M.
- Venue
- Anaerobe
- Publisher
- Elsevier BV
- Published
- 2017-06
- Volume
- 45
- Pages
- 86-100
- ISSN
- 1075-9964 (ISSN-L)
- PMC
- PMC5466893
- OpenAlex
- W2593518051
- Cited by
- 242
- References
- 45
- Citations by year
- 2026: 24 · 2025: 35 · 2024: 34 · 2023: 26 · 2022: 32 · 2021: 23 · 2020: 30 · 2019: 22 · 2018: 13 · 2017: 3
- FWCI
- 14.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Anaerobe (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Ruth L. Kirschstein National Research Service (T32OD011130)
- National Institutes of Health (R35GM119438 (CMT))
- career development award in metabolomic (K01GM109236 (CMT))
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
- Keywords
- Clostridium difficile, secondary bile acids, spore germination, toxin production, gut microbiota, colonization resistance, taurocholate, deoxycholate, ribotypes, strain differences, Clostridium difficile infection, growth kinetics
- MeSH terms
- Gastrointestinal Microbiome, Animals, Antibiosis, Anti-Bacterial Agents, Bacterial Toxins, Bile Acids and Salts, Humans, Spores, Bacterial, Clostridioides difficile, Gastrointestinal Tract, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
